{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Lobbying and Lobbyists", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Mylan Inc", "name": "organizations", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/09/02/business/dealbook/rising-drug-prices-put-big-pharmas-lobbying-to-the-test.html", "document_type": "article", "byline": {"person": [{"lastname": "CHON", "firstname": "Gina", "role": "reported", "organization": "", "rank": 1}], "original": "By GINA CHON"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "368", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Drug makers have spent $2.3 billion lobbying Congress over the last decade, which may explain why lawmakers have done little to curb drug prices.", "pub_date": "2016-09-02T04:00:00+0000", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Rising Drug Prices Put Big Pharma\u2019s Lobbying to the Test", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "Drug makers have spent $2.3 billion lobbying Congress over the last decade, which may explain why lawmakers have done little to curb drug prices....", "_id": "57c878a795d0e021d7983e06", "slideshow_credits": null, "abstract": null}